Wave Life Sciences to present on siRNA program in obesity, RNA editing

Wave Life Sciences announced upcoming presentations at the 2nd Annual Obesity & Weight Loss Drug Development Summit and the 5th Annual RNA Editing Summit, both taking place in Boston on June 11-13 and June 18-20, respectively. “Our presentations at these upcoming conferences highlight the potential of our growing, wholly owned pipeline, where we are combining novel genetic insights with our best-in-class siRNA and RNA editing capabilities to develop new treatment approaches for rare and common diseases with high unmet needs,” said Erik Ingelsson, MD, PhD, Chief Scientific Officer at Wave Life Sciences. “Our INHBE silencing program reimagines obesity treatment, focusing not just on weight loss, but on the restoration and maintenance of a healthy metabolic profile. As we will highlight at the Obesity Summit, this profile may also overcome challenges with the GLP-1 class, including unwanted side effects, poor adherence, and rebound weight gain. With RNA editing, we continue to lead the field with our WVE-006 program in Alpha-1 antitrypsin deficiency, where we have initiated our RestorAATion-2 study for individuals with AATD and expect to deliver proof-of-mechanism data this year, which would be the first-ever for RNA editing. In addition to WVE-006, we are advancing a pipeline of RNA editing therapeutics across a range of high-impact hepatic and extra-hepatic targets, and this work is being accelerated using our proprietary ‘Edit-verse’ that maps the editable gene-disease network. We are looking forward to presenting this pioneering work at the summits.”